CUMYL-CB-MEGACLONE
Designer drug
Pharmaceutical compound
![]() | |
Legal status | |
---|---|
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C25H26N2O |
Molar mass | 370.496 g·mol−1 |
3D model (JSmol) | |
| |
|
CUMYL-CB-MEGACLONE (CUMYL-CBMGACLONE, SGT-273) is a gamma-carboline based synthetic cannabinoid receptor agonist that has been sold as a designer drug, first being identified in Hungary in April 2020.[1]
See also
- 5F-CUMYL-PEGACLONE
- CUMYL-5F-P7AICA
- CUMYL-CH-MEGACLONE
- CUMYL-BC-HPMEGACLONE-221
- CUMYL-CBMINACA
- CUMYL-THPINACA
References
Receptor (ligands) |
| ||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (modulators) |
| ||||||||||||||||||||||||||||||
Enzyme (modulators) |
| ||||||||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||||||||
|